Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Mary Chriselda Antony Oliver und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, United Kingdom. Hauptthemen laut MEDLINE: Elephantiasis, Filarial, Mass Drug Administration, Cost-Benefit Analysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, World Health Organization, Gates Foundation.
Abstract (Originalsprache)
Background
The Global Programme to Eliminate Lymphatic Filariasis (GPELF) aims to reduce and maintain infection levels through mass drug administration (MDA), but there is evidence of ongoing transmission after MDA in areas where Culex mosquitoes are the main transmission vector, suggesting that a more stringent criterion is required for MDA decision making in these settings.
Methods
We use a transmission model to investigate how a lower prevalence threshold (<1% antigenemia [Ag] prevalence compared with <2% Ag prevalence) for MDA decision making would affect the probability of local elimination, health outcomes, the number of MDA rounds, including restarts, and program costs associated with MDA and surveys across different scenarios. To determine the cost-effectiveness of switching to a lower threshold, we simulated 65% and 80% MDA coverage of the total population for different willingness to pay per disability-adjusted life-year averted for India ($446.07), Tanzania ($389.83), and Haiti ($219.84).
Results
Our results suggest that with a lower Ag threshold, there is a small proportion of simulations where extra rounds are required to reach the target, but this also reduces the need to restart MDA later in the program. For 80% coverage, the lower threshold is cost-effective across all baseline prevalences for India, Tanzania, and Haiti. For 65% MDA coverage, the lower threshold is not cost-effective due to additional MDA rounds, although it increases the probability of local elimination. Valuing the benefits of elimination to align with the GPELF goals, we find that a willingness to pay per capita government expenditure of approximately $1000–$4000 for 1% increase in the probability of local elimination would be required to make a lower threshold cost-effective.
Conclusions
Lower Ag thresholds for stopping MDAs generally mean a higher probability of local elimination, reducing long-term costs and health impacts. However, they may also lead to an increased number of MDA rounds required to reach the lower threshold and, therefore, increased short-term costs. Collectively, our analyses highlight that lower target Ag thresholds have the potential to assist programs in achieving lymphatic filariasis goals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge, United Kingdom.
- Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom.
- Neglected Tropical Diseases Support Centre, The Task Force for Global Health, Decatur, Georgia, USA.
- Centre for Mathematical Modelling of Infectious Disease and Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, United Kingdom.
- School of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, United Kingdom.
- Mathematics Institute and the Zeeman Institute for Systems Biology and Infectious Disease Epidemiological Research, University of Warwick, Coventry, United Kingdom.
Förderung
- Wellcome Trust
- World Health Organization
- Gates Foundation
- Bill & Melinda Gates Foundation
- Health Data Research UK
- The Alan Turing Institute Wellcome
Zitieren
APA
Antony Oliver, M. C., Graham, M., Gass, K. M., Medley, G. F., Clark, J., Davis, E. L., Reimer, L. J., King, J. D., Pouwels, K. B., & Hollingsworth, T. D. (2024). Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae108
Vancouver
Antony Oliver MC, Graham M, Gass KM, Medley GF, Clark J, Davis EL, et al. Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae108
BibTeX
@article{AntonyOliver2024,
author = {Antony Oliver, Mary Chriselda and Graham, Matthew and Gass, Katherine M and Medley, Graham F and Clark, Jessica and Davis, Emma L and Reimer, Lisa J and King, Jonathan D and Pouwels, Koen B and Hollingsworth, T Déirdre},
title = {Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae108}
}
EUVIMED